Etrolizumab
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Etrolizumab (Roche) is a humanized anti-beta7 integrin subunit monoclonal antibody. The drug was discovered by Genentech, which was acquired by Roche in 2009. Etrolizumab binds to the beta7 subunit of the alpha4-beta7 and alphaE-beta7 integrin heterodimers. This prevents the interaction of alpha 4-beta7 integrin with mucosal addressin cell adhesion molecule-1 and the interaction of alphaE-beta7 integrin with E-cadherin. In turn, this results in interference with immune cell trafficking into the intestine in a selective manner that avoids broad immunosuppression.
The drug is in late-phase development in Crohn’s disease and ulcerative colitis. The US Food and Drug Administration has granted orphan drug designation to etrolizumab for pediatric patients.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 etrolizumab : Crohn’s disease
18 etrolizumab : Ulcerative colitis
LIST OF FIGURES
11 Figure 1: Etrolizumab for Crohn’s disease – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of etrolizumab in Crohn’s disease
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of etrolizumab in Crohn’s disease
15 Figure 4: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
26 Figure 5: Etrolizumab for ulcerative colitis – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of etrolizumab for ulcerative colitis
28 Figure 7: Datamonitor Healthcare’s drug assessment summary of etrolizumab for ulcerative colitis
LIST OF TABLES
6 Table 1: Etrolizumab drug profile
7 Table 2: Ongoing pivotal trials for etrolizumab in Crohn’s disease
11 Table 3: Other late-phase trials for etrolizumab in Crohn’s disease
16 Table 4: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country ($m), 2016–25
19 Table 5: Etrolizumab drug profile
21 Table 6: Etrolizumab Phase III trials in ulcerative colitis
25 Table 7: Etrolizumab ongoing Phase III trials in ulcerative colitis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Humira 
Sign up to the